Healthcare Policy, Market Access

Telemedicine, Telehealth, Telecare, M-health — The Challenges Ahead

Telemedicine, Teleheath, Telecare, M-health — The Challenges AheadWhile the medical industry is increasingly buzzing with concepts such as telemedicne, telehealth, telecare, m-health, we are yet to see how long they take to become a standard way of care. Perhaps the more important question is: how long will telemedicine benefit from low barriers to entry and a positive innovative environment before the regulatory bodies limit the sort of freedom its providers currently enjoy?

A Closer Look at Mobile Health
Looking more closely at the mobile health industry — and healthcare apps flooding the market — it’s clear that the regulatory framework is starting to take a shape, as evident in guidance documents published in the US (Draft Guidance for Industry and Food and Drug Administration Staff – Mobile Medical Applications) and more recently in the EU (Guidelines on the Qualification and Classification of Stand-Alone Software used in Healthcare within the Regulatory Framework of Medical Devices). The documents have been criticized as having omitted the differentiation between low risk healthcare apps — such as fitness or running apps — and the higher risk apps, for example involving diabetic platforms.

Indeed, the so called “m-health” industry is a grey area characterized by fast moving technology platforms, which makes it harder for regulators to decide on a final regulation to standardize the approval, market access and reimbursement of those apps or other healthcare software.

Pitfalls of Regulation
Regulating the telemedicine market, including m-health, has the potential to stifle innovation and threaten small businesses and new entrepreneurs that feed the market. On the other hand, the public bodies’ endorsement (like the NHS in the UK) is needed to ensure public confidence in mobile health, and secure early adoption of the technologies. The balance lies somewhere in between, and the sector, I would say, is still at its infancy weighing its options between the two.

The Key Issues

  • Technology Platform

Another pertinent issue is the technological platform. If we were to envision a future where CT scanners and MRI devices send patients’ digital images straight to doctors’ smartphones via mobile networks and WiFi, there needs to be a network system that supports this — currently there isn’t.

  • Data Volume and Speed

The amount of data that needs to be transferred in the future will be huge and software developers need to make sure that the network infrastructure is aligned with their needs. Another issue is the urgency of the data to be transferred. CT scan results can take few hours or days before being pushed to the doctors’ mobiles, however, if we think of a diabetic platform similar to the recently launched Cellnovo, when a patient is hypoglycaemic, the cellular bandwidth at which the device sends signals to the mobile phone needs to be somehow prioritized. Moreover, when similar devices come into the market, cellular urgency becomes an issue.

  • Data Security

The last concern is data security that affects telemedicine as a whole, specifically stressed upon in e-health and electronic records. As the public sector considers adopting m-health, the assurance of data secrecy and protection concerns will need to be answered.
Looking Forward

In an era of chronic disease and crunched budgets, mobile health and telehealth has the potential to lead the way in improving quality of care and remote access to personalized treatment and care, however not without challenges and some bumpy rides.

About Farah Ramadan

Farah Ramadan is an analyst within the IHS Healthcare & Pharma practice. She is involved in production and analysis both for existing and new products, as well as multi client studies. Farah holds a Masters in International Health Management from Imperial College, UK, and has experience in statistics production and dissemination. She specializes in healthcare policy and emerging markets.

Discussion

No comments yet.

Leave a Comment

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Enter your email address to follow this blog and receive notifications of new posts by email.

Download extract from IHS Flexible Pricing strategies multi client study
Drug Price Erosion Multi Client Study extract download

About This Blog

In this blog, our experts share regular insights on the global life sciences industry. Join us as we look at issues in healthcare policy, market access, pricing and reimbursement and R&D. Comments are welcome!
40 countries covered. Download a sample chapter on Brazil
Download a complimentary white paper on market-access risk ratings
Download a sample of the primary research and analysis on French P&R reform

Follow IHS Life Sciences on Twitter

Follow

Get every new post delivered to your Inbox.

Join 319 other followers